Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...
The CEO of obesity drugmaker Novo Nordisk and heads of other Danish companies met on Thursday with Denmark's Prime Minister ...
The head of Ozempic maker Novo Nordisk A/S is among business executives who are meeting the Danish prime minister to discuss ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...
President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...
In 2018, the world learned Novo Nordisk’s name when the company released semaglutide as Ozempic. Novo even created a jingle. Oh oh oh Ozempic! The cheers for semaglutide would have drowned out ...
President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and diabetes drugs exploding in popularity, even more expensive for Americans.
The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.
A Scandinavian economic behemoth, Novo Nordisk is the highest-valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many of ...